AusperBio Secures China CDE Clearance for Phase III Clinical Trial of AHB-137 in Chronic Hepatitis B,PR Newswire Healthring
AusperBio Secures China CDE Clearance for Phase III Clinical Trial of AHB-137 in Chronic Hepatitis B Shanghai, China – July 21, 2025 – AusperBio, a pioneering biopharmaceutical company dedicated to developing innovative therapies for viral diseases, is pleased to announce that it has received clearance from the China Center for Drug Evaluation (CDE) of the … Read more